These findings provide strong evidence and rationale for targeting both UBR5 and PD-L1 as a novel approach to enhance the efficacy of immune checkpoint blockade-based therapy against breast cancer, particularly TNBC. The gene discussed is UBR5; the disease is breast cancer.